Search the Newsreel

Baxter Turnaround Efforts Continue Under New Management Team

Baxter International (BAX) is undergoing a turnaround under new management, following challenges in 2022-2023. Despite a successful Baxalta spinoff in 2015, the company faced financial difficulties exacerbated by the Hillrom acquisition, inflation, and weak medical utilization. However, with elevated medical utilization, easing supply chain …

BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract

Baxter International Inc. BAX reported second-quarter 2026 adjusted earnings per share (EPS) from continuing operations of 56 cents, which topped the Zacks Consensus Estimate of 36 cents by 55.6%. The bottom line declined 5% from the year-ago quarter's level. On a GAAP basis, the …

Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress

Baxter International (BAX) shares surged after the company announced better-than-expected Q2 financial results and raised its fiscal 2026 guidance. The hospital product maker reported adjusted earnings of 54 cents per share and sales of $2.96 billion, exceeding analyst consensus. This positive performance was primarily …

Baxter’s shares soar by 17% after reporting positive Q2

Baxter reported a 5% increase in Q2 revenues to $2.96bn, driven by strong performance in its medical products and therapies segment, which led to a 17% surge in its share price on the NYSE. The company raised its 2026 outlook for sales growth and …

Baxter International stock hits 52-week high at 29.04 USD

Baxter International stock recently hit a 52-week high of $28.94 and is currently trading at $29.53, reflecting strong investor confidence and significant year-to-date returns. InvestingPro analysis indicates the stock may be slightly overvalued, though the company's recent Q2 earnings and revenue surpassed analyst expectations, …

Baxter (NYSE:BAX) Reports Upbeat Q2 CY2026, Stock Jumps 16.1%

Baxter International (NYSE:BAX) reported strong Q2 CY2026 results, surpassing analysts' revenue expectations with a 5.3% year-on-year sales increase to $2.96 billion and a non-GAAP profit significantly above consensus estimates. The healthcare company also raised its full-year Adjusted EPS guidance, leading to a 16.1% jump …

Baxter International Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:BAX) 2026-07-30

Baxter International Inc. released its Q2 2026 earnings call presentation on July 30, 2026. The company reported an EPS of $0.56, beating estimates by $0.19, and revenue of $2.96 billion, exceeding expectations by $164.49 million with a 5.34% year-over-year increase. This article from SA …

Baxter raises annual profit forecast on strong demand for IV solutions

Medical products maker Baxter International has raised its annual profit forecast and exceeded Wall Street's quarterly estimates, driven by strong sales of IV solutions and other medical products. The company's shares jumped 14% premarket, despite ongoing challenges with its Novum infusion pump shipments. Baxter …

Baxter stock surges 13% on earnings and revenue beats

Baxter International Inc. (NYSE:BAX) reported Q2 results that exceeded analyst expectations, leading to a 12.84% surge in its stock. The company's adjusted EPS and revenue surpassed estimates, attributed partly to an unexpected tariff refund. Baxter also raised its full-year 2026 financial outlook for both …

Baxter Reports Second-Quarter 2026 Results

Second-quarter sales of $2.96 billion increased 5% on both a reported and organic basis,1, 2 reflecting growth in all segments and divisions Second-quarter U.S. GAAP3 diluted earnings per share (EPS) of $0.26; adjusted diluted EPS of $0.56 Company raises full-year 2026 financial outlook DEERFIELD, …

Earnings Flash (BAX) Baxter International Inc. Posts Q2 Adjusted EPS $0.56 per Share, Vs. FactSet Est of $0.37

Baxter International Inc. reported strong second-quarter results, with adjusted EPS coming in at $0.56 per share, significantly exceeding the FactSet estimate of $0.37. This flash report indicates a positive earnings surprise for the medical products company.

Baxter turnaround gains traction with strong results, higher outlook

Baxter International's stock surged following strong financial results and a raised outlook, signaling progress in the company's turnaround efforts. This positive performance was reported by Jon Asplund of Bloomberg on July 30, 2026. This development suggests growing investor confidence in Baxter's strategic changes.

Baxter International Inc (BAX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Baxter International Inc (BAX), detailing its current valuation score, P/E ratio, and comparison to industry peers. As of the update on July 29, 2026, the company's valuation score is 7.95, placing it 118th in the Healthcare Equipment …

Baxter International (BAX) Earnings Date and Reports 2026 $BAX

BAXTER INTERNATIONAL INC Quarterly Earnings Report

Baxter International Number of Employees 2026 | Employee Count & Headcount Data

Baxter International (BAX) had approximately 37,088 employees worldwide as of March 2026, marking a 9.5% decline from 2023. The company is actively hiring with 1,578 job postings in 2026, though new postings have slowed. North America holds the largest share of its workforce, and …

Baxter International Inc (BAX) Institutional Confidence

Baxter International Inc (BAX) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding stands at 108.01%, a slight decrease from the previous quarter. Richard Pzena is the largest institutional shareholder, holding 12.49% of outstanding …

Baxter earnings loom as company unveils new segment structure

Baxter International Inc. is set to report its second-quarter earnings, debuting a new streamlined reporting structure. Analysts anticipate adjusted earnings of 37 cents per share on revenue of $2.8 billion, with a cautious "Hold" rating from most analysts despite recent price target increases. Investors …

Baxter Earnings: What To Look For From BAX

Baxter Earnings: What To Look For From BAX Healthcare company Baxter International (NYSE:BAX) will be reporting results this Thursday before market open. Here's what you need to know. Baxter beat analysts' revenue expectations last quarter, reporting revenues of $2.70 billion, up 2.9% year on …

Baxter (BAX) Stock May Be 19% Undervalued On Cash Flow

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Baxter International stock has delivered a steep decline of about 64.6% over the past five years, yet current valuation checks suggest the shares …

Abaxx Exchange Market Data Now Available via Bloomberg Solutions

TORONTO, July 29, 2026 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today …

Baxter International Inc (BAX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Baxter International Inc. (BAX), detailing its volatility, financial risk, and investment risk. BAX has a risk assessment score of 6.65, ranking 51 out of 199 in the Healthcare Equipment & Supplies industry, with a beta of 0.65. …

Stifel raises Baxter stock price target on segment restructuring By Investing.com

Stifel increased its price target for Baxter International Inc. to $24.00 from $19.00, maintaining a Hold rating, attributing the adjustment to the company's recent segment restructuring. Baxter transitioned from three reporting segments to two, with Medical Products & Therapies now representing about 70% of …

Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution

Baxter International has voluntarily recalled one lot of cefazolin in dextrose injection after a report of cardboard contamination in an IV infusion bag. The recalled batch, LD175708, was distributed across the U.S. and poses risks such as blood vessel blockages, immune system activation, and …

Stifel Adjusts Price Target on Baxter International to $24 From $19, Maintains Hold Rating

Stifel has raised its price target for Baxter International (BAX) to $24 from $19, while maintaining a 'Hold' rating on the stock. This adjustment comes amidst other analyst recommendations and company news, including Goldman Sachs and TD Cowen also adjusting their price targets for …

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Baxter International (BAX)

This article provides analyst insights for two healthcare companies: InflaRx (IFRX) and Baxter International (BAX). InflaRx received a "Strong Buy" consensus with a significant upside, based on Buy ratings from LifeSci Capital and Oppenheimer. Baxter International holds a "Hold" consensus, with TD Cowen and …

Why Baxter (BAX) Stock Is Up Today

Why Baxter (BAX) Stock Is Up Today What Happened? Shares of healthcare company Baxter International (NYSE:BAX) jumped 3.6% in the afternoon session after TD Cowen raised its price target on the stock to $24 from $20. The firm maintained its hold rating on the …

BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION

Baxter International Inc. has issued a voluntary nationwide recall of Lot LD175708 of Cefazolin in Dextrose Injection, USP, due to the presence of cardboard particulate matter found in the solution. The recalled product, a 2G / 100ML (20MG / ML) single-dose infusion bag, carries …

Baxter International Q2 2026 Earnings Preview — July 30, Street Expects $0.37 EPS

Baxter International is expected to report Q2 2026 earnings of $0.37 per share on $2.79 billion in revenue on July 30. This EPS estimate reflects a significant 37.3% year-over-year decline and a 15.9% cut over the past 90 days by analysts, signaling considerable margin …

Baxter International Inc (BAX) Income Statement

This article provides a detailed income statement for Baxter International Inc (BAX), offering both quarterly and annual financial insights. It includes key metrics such as total revenue, cost of revenue, operating expenses, research and development expenses, and net income, allowing users to analyze the …

Baxter International Inc (BAX) Cash Flow

This article provides a comprehensive overview of Baxter International Inc's (BAX) cash flow statement, including operating, investing, and financing activities. It presents detailed quarterly and annual financial data, highlighting changes in various cash flow components. The report also defines key financial metrics such as …

Baxter International Inc (BAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Baxter International Inc (BAX) by business segment and geographical region. As of April 6 (updated), the company's largest business segments are Infusion Therapies and Technologies and Care and Connectivity Solutions, while the United States accounts for …

Abaxx Technologies Inc Revenue Breakdown – TSX:ABXX

Bank of New York Mellon Corp Reduces Holdings in Baxter International Inc. $BAX

Bank of New York Mellon Corp decreased its stake in Baxter International Inc. by 13.1% in the first quarter, selling 396,247 shares and now owning 2,623,255 shares worth $44.07 million. Other institutional investors had mixed activity, with some increasing their holdings significantly. Analysts have …

Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?

Baxter International Inc. (BAX) is scheduled to release its second-quarter 2026 results on July 30, with expectations of continued operational headwinds impacting performance. The company anticipates revenue decline and a significant drop in earnings per share due to manufacturing inefficiencies, inflationary pressures, and issues …

Baxter stock trades steadily as spin-off and transformation reshape earnings profile

Baxter International is undergoing a significant transition, reshaping its earnings profile through the spin-off of its Renal Care and Acute Therapies businesses into Vantive. While this restructuring led to lower revenue in fiscal 2023, the company maintained stable adjusted EPS and improved operating margins …